Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Gold as soon as Publ. Version/Full Text is submitted to ZB.
Temsirolimus acts as additive with bendamustine in aggressive lymphoma.
Ann. Hematol. 95, 403-407 (2015)
The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-kinase (PI3K)/AKT signalling pathway. It plays a pivotal role in the control of cell proliferation, survival, and angiogenesis with multiple and frequent dysregulations of this pathway in human tumors. Temsirolimus is an intravenous drug, specifically inhibiting the mTOR pathway. Bendamustine is well known for its clinical activity in indolent non-Hodgkin-lymphoma (NHL) and has lately shown clinical activity in mantle cell lymphoma (MCL). Here, we present a case report of temsirolimus in combination with bendamustine and rituximab leading to a CR in a pretreated male. In addition, our in vitro data underlines the additive and synergistic efficacy in cell growth reduction of temsirolimus combined with bendamustine in MCL cell lines and in DLBCL cell lines. Furthermore, as an underlying mechanism of this additive, effects on cell cycle inhibition and apoptosis induction could be identified.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Bendamustine ; Dlbcl ; Mcl ; Temsirolimus; Mantle Cell Lymphoma; Non-hodgkin-lymphoma; 1st-line Treatment; Plus Rituximab; Cycle Arrest; Mtor; Combination; Indolent; Trial; Multicenter
ISSN (print) / ISBN
0939-5555
e-ISSN
1432-0584
Journal
Annals of Hematology
Quellenangaben
Volume: 95,
Issue: 3,
Pages: 403-407
Publisher
Springer
Publishing Place
New York
Reviewing status
Peer reviewed
Institute(s)
Institute of Functional Epigenetics (IFE)